PROGESTINS & CARDIOVASCULAR DISEASE
Recommened Journal Articles:
Adams, M.R., et al., “Medroxyprogesterone acetate antagonized inhibitory effects of conjugatedequine estrogens on coronary artery atherosclerosis.” Arterioscler Thromb Vasc Biol, January 1997, 17 (1):217-21.
Bush, Trudy L., “Preserving cardiovascular benefits of hormone replacement therapy. Jorunal of Reproductive Medicine, March 2000, 45, 3 (Supplement): 259-72.
Hully, S., et al., “Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.”Journal of the American Medical Association, August 19, 1998, 280 (7):605-13.
Miyagawa, K., et al., “Medroxyprogesterone acetate interferes with ovarian steroid protection against coronary vasospasm.” Nature Medicine,1997, 3:324-27.
Rosano, G.M., et al., “Medroxyprogesterone but not natural progesterone reverses the beneficial effect of estradiol-17b upon exercise induced myocardial ischemia: a double-blind cross-over study.” Circulation, 1996; 94: 1-18.
Rosano, G.M., et al., “Cardiovascular pharmacology of hormone replacement therapy.” Drugs & Aging, September 1999, 15 (3):219-34.